Previous 10 | Next 10 |
BiondVax to Present at BIO CEO & Investor Conference BiondVax to Present at BIO CEO & Investor Conference PR Newswire JERUSALEM , Feb. 15, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on de...
BiondVax to Present at Edison Group's Open House Conference PR Newswire JERUSALEM , Jan. 26, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative pro...
BiondVax to Present at H.C. Wainwright Bioconnect Virtual Conference PR Newswire JERUSALEM , Jan. 10, 2022 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innov...
NEW YORK, NY / ACCESSWIRE / January 3, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV). About BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) is a biopha...
BiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment PR Newswire JERUSALEM , Dec. 29, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a biopharmaceutical company ...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +21%, Regencell Bioscience (NASDAQ:RGC) +17%, BridgeBio Pharma BBIO +13%, ImmunityBio (NASDAQ:IBRX) +8%, BiondVax Pharmaceuticals BVXV +8%. Losers: Biofrontera (NASDAQ:BFRI) -21%, Microbot Medical (...
3 Hot Penny Stocks to Add to Your 2022 Watchlist With the new year only a few days away, there is plenty of bullish sentiment with penny stocks right now. Although the last month or so has not been an easy time for those who invest in either penny stocks or blue chips , we are seein...
BiondVax Pharmaceuticals (NASDAQ:BVXV) appointed former CFO of GlaxoSmithKline's (NYSE:GSK) global vaccines business Jay Green to its board of directors. Green recently completed a six-year term as Senior Vice President Finance and CFO of GlaxoSmithKline's global vaccines busi...
Former CFO of GSK's Global Vaccines Business Mr. Jay Green Joins BiondVax's Board of Directors PR Newswire JERUSALEM , Dec. 27, 2021 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing...
Gainers: PyroGenesis Canada (NASDAQ:PYR) +72%. Microbot Medical MBOT +50%. CollPlant Biotechnologies CLGN +32%. Future FinTech FTFT +41%. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. Spruce Biosciences (NASDAQ:SPRB) +31%. Tarena International TEDU +19%. CNF...
News, Short Squeeze, Breakout and More Instantly...
BiondVax Pharmaceuticals Ltd. Company Name:
BVXV Stock Symbol:
NASDAQ Market:
BiondVax (NASDAQ: BVXV) , a biotechnology company, today announced a change of its corporate name to Scinai Immunotherapeutics, which will debut on the Nasdaq under a new symbol, SCNI, on Sept. 7, 2023. In the past two years, the company has revamped its senior management team and pharmaceuticals...
JERUSALEM, Sept. 06, 2023 (GLOBE NEWSWIRE) -- via IBN -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) , a biopharmaceutical company, is pleased to announce today a change of its corporate name to Scinai Immunotherapeutics Ltd. (“Scinai ”). In the past two years, the Company ...
BiondVax (NASDAQ: BVXV) , a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently recei...